Sri Krishna Pharmaceuticals Limited
Sri Krishna Pharmaceuticals Limited, often referred to as SKPL, is a prominent player in the pharmaceutical industry, headquartered in India. Established in 1975, the company has made significant strides in the production of active pharmaceutical ingredients (APIs) and formulations, catering to both domestic and international markets. With a strong operational presence across various regions, SKPL focuses on a diverse range of therapeutic segments, including anti-infectives, cardiovascular, and central nervous system medications. The company is renowned for its commitment to quality and innovation, offering unique products that meet stringent regulatory standards. Over the years, Sri Krishna Pharmaceuticals has achieved notable milestones, solidifying its market position as a trusted supplier in the pharmaceutical sector. Its dedication to research and development, coupled with a robust manufacturing infrastructure, underscores its reputation for excellence in the industry.
DitchCarbon Score
How does Sri Krishna Pharmaceuticals Limited's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Chemicals industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Sri Krishna Pharmaceuticals Limited's score of 9 is lower than 57% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Sri Krishna Pharmaceuticals Limited's reported carbon emissions
In 2023, Sri Krishna Pharmaceuticals Limited reported significant carbon emissions, totalling approximately 1,089,283,000 kg CO2e from Scope 1 and about 315,771,000 kg CO2e from Scope 2. This marks an increase from 2022, where emissions were around 882,002,000 kg CO2e for Scope 1 and approximately 387,681,000 kg CO2e for Scope 2. Despite the lack of specific reduction targets or initiatives disclosed, the company is expected to align with industry standards for climate commitments. As a pharmaceutical manufacturer, Sri Krishna Pharmaceuticals operates in a sector that is increasingly focused on reducing carbon footprints and enhancing sustainability practices. The absence of Scope 3 emissions data suggests a potential area for future reporting and improvement. Overall, while the current emissions figures indicate a substantial environmental impact, the company’s future climate commitments and strategies remain to be clarified.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2022 | 2023 | |
|---|---|---|
| Scope 1 | 882,002,000 | 0,000,000,000 |
| Scope 2 | 387,681,000 | 000,000,000 |
| Scope 3 | - | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Sri Krishna Pharmaceuticals Limited is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
